Astria Therapeutics Completes Underwritten Offering of Common Stock

Astria Therapeutics Completes Underwritten Offering of Common Stock

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Astria Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases, completed its underwritten registered direct offering of 10,340,000 shares of its common stock. The shares were priced on January 30, 2024 at an offering price of $12.09 per share and the offering closed on February 1, 2024. Astria received gross proceeds of approximately $125 million before deducting underwriting discounts and commissions and other offering expenses.  

The WilmerHale team representing Astria consisted of Rosemary Reilly, Molly Fox, Jeffries Oliver-Li, Andrea Sorrentino, Kevin Cheng and Arpi Youssoufian, with assistance from Heidi Treiber, Ben Lobley and Mark Devine. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel